Physician profile
Mark Charles Walters
NPI 1588753610
$68,997.54
in general payments reported to CMS, 2019-2025
8 companies · $9,212 in 2025
The $9,212 reported for 2025 was more than what 84% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,128 · 2020: $4,950 · 2021: $6,930 · 2022: $5,670 · 2023: $17K · 2024: $19K · 2025: $9,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $35K · Travel and Lodging: $9,722 · Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $35,202.02 |
| Travel and Lodging | $9,721.90 |
| Food and Beverage | $395.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $48,575.36 | 2021-2025 | |
| Sanofi US Services INC. | $9,281.63 | 2023 | |
| Csl Behring | $5,919.33 | 2019 | |
| Spark Therapeutics, INC. | $4,350.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $600.00 | 2020 | |
| Bioverativ Therapeutics INC. | $208.42 | 2019 | |
| Genetix Biotherapeutics INC | $62.80 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.